Biotechnology • Informatics • Medical Instrumentation • Pharmaceuticals
Scott Minick joined the firm in 1998 and was a Managing Director through January 2010 before becoming President and CEO of BIND Therapeutics, which he led through its IPO in 2013. Mr. Minick remains an active board member of several ARCH portfolio companies, including Chiasma.
Mr. Minick was instrumental in the startup, development and financing of numerous portfolio companies including XenoPort (XNPT), FastTrack Systems (acq. by Medidata Solutions), MedVantx, Achaogen, BIND Therapeutics (BIND), Celula, Adolor (ADLR) and Chiasma. Mr. Minick formerly served as Chairman of Xcyte Therapies (XCYT) through its IPO in 2004 and subsequent acquisition of Cyclacel Pharmaceuticals (CYCC).
From 1995 until 1998, Mr. Minick was director, President and COO of SEQUUS Pharmaceuticals, a public biopharmaceutical company that was acquired by ALZA and subsequently Johnson & Johnson. From 1994 to 1995, he served as a director, President and CEO of OncoTherapeutics, a private biotechnology company. Prior to that, Mr. Minick co-founded and was a director, President and CEO of LXR Biotechnology from startup through its IPO. From 1981 to 1993, he was an executive of Baxter Healthcare, holding leadership positions in the device, service and diagnostics businesses. Previously, Mr. Minick was an executive at Eli Lilly.
He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University and a B.A. with Honors from the University of California at San Diego.